Aldeyra Therapeutics, a biotech developing treatments for rare skin and eye diseases, has raised $12 million in an initial public offering. The company offered 1.5 million shares at $8 per share, below its $10 to $12 range. Domain Associates and Johnson & Johnson Development held 50.1% and 44.5% pre-IPO stakes in the company, respectively. Aldeyra raised about $16 million in VC funding prior to the offering, having most recently secured $6.8 million of Series B funds at a $21 million valuation in August 2013. ALDX shares closed at $6.99 on their debut.